Gilteritinib
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors
Conditions
Advanced Solid Tumors, Acute Myeloid Leukemia
Trial Timeline
May 3, 2016 → Jul 28, 2020
NCT ID
NCT02561455About Gilteritinib
Gilteritinib is a phase 1/2 stage product being developed by Astellas Pharma for Advanced Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02561455. Target conditions include Advanced Solid Tumors, Acute Myeloid Leukemia.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03409081 | Pre-clinical | Completed |
| NCT03070093 | Pre-clinical | Completed |
| NCT07140016 | Phase 1 | Recruiting |
| NCT06734585 | Pre-clinical | Completed |
| NCT04699877 | Phase 1 | Completed |
| NCT02561455 | Phase 1/2 | Completed |
| NCT02181660 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Solid Tumors